NO971566L - Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF - Google Patents

Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF

Info

Publication number
NO971566L
NO971566L NO971566A NO971566A NO971566L NO 971566 L NO971566 L NO 971566L NO 971566 A NO971566 A NO 971566A NO 971566 A NO971566 A NO 971566A NO 971566 L NO971566 L NO 971566L
Authority
NO
Norway
Prior art keywords
kgf
diabetes mellitus
treating diabetes
mammals
diabetes
Prior art date
Application number
NO971566A
Other languages
English (en)
Norwegian (no)
Other versions
NO971566D0 (no
Inventor
Sharon Lea Aukerman
Glenn Francis Pierce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO971566D0 publication Critical patent/NO971566D0/no
Publication of NO971566L publication Critical patent/NO971566L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO971566A 1994-10-13 1997-04-04 Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF NO971566L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32334094A 1994-10-13 1994-10-13
US32347594A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (2)

Publication Number Publication Date
NO971566D0 NO971566D0 (no) 1997-04-04
NO971566L true NO971566L (no) 1997-04-14

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
NO971566A NO971566L (no) 1994-10-13 1997-04-04 Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
NO19971568A NO318761B1 (no) 1994-10-13 1997-04-04 Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19971568A NO318761B1 (no) 1994-10-13 1997-04-04 Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Country Status (23)

Country Link
EP (2) EP0804479B1 (cs)
JP (2) JP4426646B2 (cs)
KR (1) KR100278597B1 (cs)
CN (1) CN1168678A (cs)
AT (2) ATE237633T1 (cs)
AU (1) AU3707795A (cs)
BG (2) BG101392A (cs)
BR (2) BR9509269A (cs)
CA (2) CA2202075C (cs)
CZ (3) CZ297328B6 (cs)
DE (2) DE69530403T2 (cs)
DK (2) DK0785948T3 (cs)
EE (2) EE9700225A (cs)
ES (2) ES2273338T3 (cs)
FI (2) FI971420L (cs)
HU (2) HU226168B1 (cs)
NO (2) NO971566L (cs)
NZ (2) NZ505502A (cs)
PL (2) PL320484A1 (cs)
PT (2) PT785948E (cs)
SI (2) SI0785948T1 (cs)
SK (2) SK284534B6 (cs)
WO (2) WO1996011950A1 (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008771A1 (en) 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
ES2227527T3 (es) 1993-06-29 2005-04-01 Chiron Corp Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
EP1334981B1 (en) * 1994-10-13 2011-01-26 Swedish Orphan Biovitrum AB (publ) Method for purifying keratinocyte growth factors
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
DK0822943T3 (da) * 1995-04-27 1999-11-29 Cooperatie Cosun U A Inulinderivater
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
ATE263239T1 (de) * 1996-10-15 2004-04-15 Amgen Inc Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
RU2003125643A (ru) * 2001-02-06 2005-01-20 Мерк Патент ГмбХ (DE) Модифицированный фактор роста кератиноцита (kgf) с уменьшенной иммуногенностью
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
JP2005500390A (ja) * 2001-08-21 2005-01-06 カイロン コーポレイション Ｋｇｆポリペプチド組成物
PT1827483E (pt) 2004-12-15 2014-09-25 Swedish Orphan Biovitrum Ab Publ Formulações terapêuticas do fator de crescimento de queratinócitos
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
US5145225A (en) * 1988-07-27 1992-09-08 Muller George M Carpet stretcher
WO1990008771A1 (en) * 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
FI954541A7 (fi) * 1993-03-26 1995-11-23 Amgen Inc Keratinosyyttikasvutekijän terapeuttisia käyttöjä
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
ES2227527T3 (es) * 1993-06-29 2005-04-01 Chiron Corp Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
EP0712314A1 (en) * 1993-08-02 1996-05-22 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
WO1996011949A3 (en) 1996-12-12
SI0785948T1 (en) 2003-08-31
SK284534B6 (sk) 2005-06-02
DE69535264T2 (de) 2007-02-01
HUT78050A (hu) 1999-07-28
NO318761B1 (no) 2005-05-02
HUT78058A (hu) 1999-07-28
SI0804479T1 (sl) 2006-12-31
CA2201940A1 (en) 1996-04-25
DK0785948T3 (da) 2003-08-04
EE03975B1 (et) 2003-02-17
ATE237633T1 (de) 2003-05-15
JPH10507193A (ja) 1998-07-14
CA2202075A1 (en) 1996-04-25
DE69535264D1 (de) 2006-11-23
HU226168B1 (en) 2008-05-28
NO971568D0 (no) 1997-04-04
ES2273338T3 (es) 2007-05-01
CZ297329B6 (cs) 2006-11-15
EP0804479B1 (en) 2006-10-11
EP0785948B1 (en) 2003-04-16
WO1996011949A2 (en) 1996-04-25
BG101392A (en) 1997-10-31
JP4216329B2 (ja) 2009-01-28
PL182888B1 (pl) 2002-03-29
PT785948E (pt) 2003-09-30
JP4426646B2 (ja) 2010-03-03
DK0804479T3 (da) 2007-01-29
BG63167B1 (bg) 2001-05-31
SK45597A3 (en) 1999-02-11
FI971420A7 (fi) 1997-04-04
EE9700225A (et) 1998-02-16
KR100278597B1 (ko) 2001-01-15
PT804479E (pt) 2007-02-28
BG101408A (bg) 1997-12-30
FI971536L (fi) 1997-06-09
BR9509269A (pt) 1997-12-23
FI120040B (fi) 2009-06-15
FI971420A0 (fi) 1997-04-04
EP0785948A1 (en) 1997-07-30
FI971536A0 (fi) 1997-04-11
AU3707795A (en) 1996-05-06
CA2202075C (en) 2003-12-09
CZ105097A3 (cs) 1998-10-14
EP0804479A1 (en) 1997-11-05
FI971420L (fi) 1997-04-04
CN1168678A (zh) 1997-12-24
ES2196082T3 (es) 2003-12-16
NZ505502A (en) 2005-01-28
NO971566D0 (no) 1997-04-04
PL319784A1 (en) 1997-08-18
JPH10507080A (ja) 1998-07-14
NO971568L (no) 1997-06-12
WO1996011950A1 (en) 1996-04-25
NZ335109A (en) 2000-08-25
AU681546B2 (en) 1997-08-28
PL320484A1 (en) 1997-09-29
DE69530403T2 (de) 2003-10-30
CZ98197A3 (cs) 1998-11-11
ATE342278T1 (de) 2006-11-15
DE69530403D1 (de) 2003-05-22
CA2201940C (en) 2009-05-12
CZ297328B6 (cs) 2006-11-15
EE9700081A (et) 1997-10-15
AU3708395A (en) 1996-05-06
BR9509329A (pt) 1997-10-14
SK43197A3 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
NO971566L (no) Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
NO963785L (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
AU4838097A (en) Apparatus for the treatment of specimens
NO981810D0 (no) Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt
NO963322D0 (no) Fremgangsmåte for behandling av abstinens ved stoffmisbruk
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
FI943028A7 (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiint yvien, haavaumia aiheuttavien sairauksien hoitamiseksi
SE9603725D0 (sv) New teatment
AU3040795A (en) Method and composition for treating intestinal wounds or ulcers
NO972449L (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
SE9600120D0 (sv) Novel medical use
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers
UA30448A (uk) Спосіб формування холедоходуоденоанастомозу
AU3597695A (en) Improved method and composition for the treatment of ulcers
AUPN733195A0 (en) Improved method and composition for the treatment of ulcers
IT1285551B1 (it) Composizione e procedimento per la sterilizzazione di substrati di coltura